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Abstract. This study was designed to investigate the migratory 
behavior of adult human mesenchymal stem cells (MSC) and 
the underlying mechanism. Cell migration was assessed by 
transwell, wound healing and time-lapse in vivo motility assays. 
Pharmacological inhibitors were used to determine the potential 
mechanism responsible for cell migration and invasion. The 
tests that were implemented revealed that MSC were fairly 
migratory. Protein kinase B (AKT) was strongly activated at the 
basal level. Through our analyses we demonstrated that phar-
macological inactivation of AKT2 but not AKT1 significantly 
decreased cell migration and invasion. Although preliminary, 
collectively our results indicate that AKT2 activation plays a 
critical role in enabling MSC migration.
Introduction
Mesenchymal stem cells (MSC) are a rare population of bone 
marrow-derived non-hematopoietic fibroblast-like cells, repre-
senting ~0.001-0.01% of the nucleated cells in the marrow. 
The accessibility, ease of handling, and enormous expansion 
potential of MSC, together with their capacity for self-renewal 
(reviewed in ref. 1) and amenability to allogeneic transplanta-
tion (2), provide a nearly unlimited supply of cells for therapeutic 
applications. MSC are attractive candidates for manipulation as 
they can easily be isolated from patients, cultured in vitro, and 
autologously transplanted into patients, thus overcoming the 
difficulties related to immune rejection of transplanted cells (3). 
A significant improvement in understanding MSC biology in 
recent years has paved the way to their potential clinical use. 
In particular, MSC are emerging as novel cell-based delivery 
agents. Indeed, thanks to inherent tumor-trophic migratory 
properties, MSC could vehicle effective targeted therapy to 
isolated tumors and metastatic disease. However, defective 
migration is a major caveat in cell-based therapy as systemic 
stem cell transplantation requires efficient cell homing, and is 
therefore of utmost importance to understand the underlying 
molecular mechanisms driving MSC movement to specific 
target sites (reviewed in ref. 4).
Phosphoinositide-3 kinase (PI3K)/AKT signaling circuit 
is a well established regulator of important functions in 
cells, such as cell cycling, survival and cell growth (5). In 
addition, recent studies have demonstrated that AKT plays a 
pivotal role in cell migration and invasion (6-8). In particular, 
AKT enhances actin remodeling by a number of possibly 
interconnected mechanisms, in several cell systems. AKT 
modulates actin bundling by direct actin binding, and gener-
ates membrane protrusions through downstream activation 
of Rac1 and Cdc42 (9,10). Besides, PI3K/AKT signals induce 
also the remodeling of actin through the activation of p70S6K, 
leading to cell migration and cell invasion (11). Furthermore, 
AKT promotes actin organization and cell motility medi-
ated by a number of substrates and/or interactors, such as 
Girdin/AKT-phosphorylation enhancer (APE) (12), the actin 
bundling protein Palladin (13) and the mechano-protein and 
AKT-substrate ANKRD2 (14). Accordingly, PI3K/AKT 
signals are considered to be crucial in cell migration by 
controlling actin dynamics.
Remarkably, it has been demonstrated that AKT isoform 1 
and AKT isoform 2 exert opposing functions in breast cancer 
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cell migration and metastasis (6,7,13,15). There is little informa-
tion, however, on their role in other cell models. We therefore 
aimed to elucidate the contribution of AKT to MSC migration 
by specific pharmacological inhibition.
Materials and methods
Mesenchymal stem cell culture. Bone marrow (BM) samples 
were obtained from patients undergoing surgery at Rizzoli 
Orthopaedic Institute after obtaining informed consent. Bone 
marrow derived MSC cultures were obtained as previously 
described (16). Cells were transferred to 150-cm2 culture 
flasks with α-Modified minimum Essential medium (α-MEM; 
BioWhittaker, Lonza, Verviers, Belgium) supplemented with 
20% lot-selected fetal bovine serum (FBS; Gibco, Invitrogen, 
Paisley, UK) and GlutaMAX™ 1% (Invitrogen), incubated in 
a humidified atmosphere at 37˚C with 5% CO2 and medium 
changed every 3-4 days. When the cells reached approximately 
70-80% confluence, they were detached by mild trypsinization 
(TripLe™ Select, Invitrogen) for 5 min at 37˚C and counted. 
Then, 1/3 of them were reseeded into a new 150 cm2 flask.
MSC were recognized by their ability to proliferate in culture 
with adherent, spindle-shape morphology. The total number 
of cells obtained at each passage was extrapolated from the 
counted representative samples; the number was calculated by 
multiplying the number of cells counted by the number of flasks 
available at each passage. Cell number and cell viability were 
assessed for each passage by NucleoCounter® (ChemoMetec, 
Lillerød, Denmark), that detects non-viable cells by using propi-
dium iodide nuclear staining, and determines cell viability by 
calculating the ratio of total and non-viable cell number. Further 
characterization of MSC was performed by cytofluorimetric 
analysis of cell surface markers at passage two. MSC resulted 
positive for CD44, CD73, CD90, CD105, CD146 and negative for 
CD34 and CD45 (17). The multilineage potential was evaluated 
by differentiation assays as previously described (18). After the 
appropriate stimulations, cells positively differentiated in osteo-
genic, adipogenic and condrogenic lineages.
Drug treatments. Cells were seeded 1x104 cells/cm2 density in 
complete medium and starved overnight with 0.2% FBS medium. 
On the third day, culture was treated for 30 min with PI3K 
Inhibitor LY-294002 (#L9908, Sigma-Aldrich, St. Louis, MO, 
USA) at 10 µM and AKT Inhibitor IV (#B2311, Sigma-Aldrich) 
at 2.5 µM concentration. Inhibitor VIII (#202048, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) was used at 1 µM to inhibit 
AKT1/2 and Inhibitor XII (#124029, Calbiochem, La Jolla, CA, 
USA) was used at 5 µM for AKT2 isoform. Specific Inhibitors 
for singular isoforms were used for 1 h.
Immunofluorescence microscopy. Cells were seeded (2.5x104) 
onto glass coverslips and fixed for 10 min in 4% formaldehyde 
at RT, as described (19). After three washes in PBS, cells were 
permeabilized for 10 min in PBT (PBS + 0,1% Triton X-100), 
then incubated in blocking solution (1X PBS + 5% BSA) for 
30 min. Primary antibody anti-Vinculin (1:100, #MAB3574, 
Chemicon, Temecula, CA, USA) diluted in blocking solution 
was added and incubated for 1 h at RT. After three washes in 
1X PBS, secondary antibody anti-mouse Cy3 (1:100, #C2181, 
Sigma-Aldrich) was added diluted in 1X PBS and incubated for 
45 min at RT. Cortical actin was stained using FITC-Phalloidin 
(1:500, #P5282, Sigma-Aldrich) and added directly during 
secondary antibody incubation. Nuclei were stained by incu-
bating cells with Hoechst 33342 (1:2000, #H1399, Invitrogen) for 
10 min at RT (20). Coverslips were mounted after washes in PBS 
in Fluoromount-G (Southern Biotech, Birmingham, AL, USA) 
solution and analyzed with a NikonTiE microscope equipped with 
the fully automated A1 confocal laser that incorporates the reso-
nant scanner with a resonance frequency of 7.8 kHz that allows 
high-speed imaging (A1R), and equipped with DS-QiMc-U2 
12 bit camera. Digital images were processed using Matlab and 
ImageJ software for the analysis and Photoshop software for 
visualization purposes without biased manipulations (21).
Preparation of cell extracts and electrophoresis. Cell extracts 
were obtained as previously reported (22). Briefly, sub-confluent 
cells were directly extracted by addition of RIPA buffer (20 mM 
Tris-Cl, pH 7.0, 1% NP-40, 150 mM NaCl, 10% glycerol, 10 mM 
EDTA, 20 mM NaF, 5 mM sodium pyrophosphate, 1 mM 
Na3VO4) and freshly added Sigma-Aldrich Protease Inhibitor 
Cocktail at 4˚C for 20 min. Lysates were cleared by centrifugation. 
Equal amounts of lysates were loaded on 7,5% Bis-Tris-SDS-
polyacrylamide gels (Bio-Rad, Hercules, CA, USA), transferred 
to Immobilon-P membranes (Millipore Corporation, Billerica, 
MA, USA), probed with the indicated antibodies by using 
SNAP i.d.® 2.0 System (Millipore Corporation) and detected by 
chemiluminescence with Supersignal kit (Pierce, Rockford, IL, 
USA).
The primary antibodies used: anti-actin 1:1,000 (#sc-8432), 
anti-AKT 1:1,000 (#sc-1619), from Santa Cruz Biotechnology 
and anti-pS473AKT 1:1,000 (#4051) from Cell Signalling 
Technology (Denvers, MA, USA). Secondary antibodies were 
anti-mouse (#sc-2031) and anti-rabbit (#2317) HRP-conjugated 
from Santa Cruz Biotechnology and were used 1:5,000 dilution.
Scratch wound healing assay. Scratch wound tests were 
performed in a 6-well plate in confluent culture. Cell suspen-
sions (1,000 µl) containing 3x105 cells in 0.2% FBS medium 
were added to each well and left overnight to allow cell adhe-
sion. Immediately before starting the assay, the scratch was 
performed by using 200 µl tips. Closing of the wound was 
monitored along 24 h with a Nikon Eclipse TE2000-U inverted 
microscope, and calculated as Migrated Cell Surface Area/Total 
Surface Area x 100 with a web-based image automated analysis 
software developed by the Koumoutsakos group (CSE Lab), at 
ETH Zürich (23).
Cytotoxicity and cell proliferation assay. Cytotoxicity and 
cell proliferation were evaluated using AlamarBlue® kit (AbD 
Serotec, Oxford, UK) according to the manufacturer's instruc-
tions. Briefly, the test was performed in 96-well plate by seeding 
3x103/cm2 in 0.2% FBS medium and treated or not with inhibi-
tors. The reagent was added to the sample for 4 h incubation, at 
the end of which the indicator passes from the Redox oxidized 
form (blue) to the reduced form (red) according to the number of 
cells that are found in the sample. Absorbance was monitored at 
570 nm and 600 nm.
Cell cycle and apoptosis analysis. For detection and quantifica-
tion of cell cycle distribution samples containing 5x105 cells were 
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harvested by centrifugation, fixed in cold ethanol and subjected 
to propidium iodide (PI) staining as previously described (24).
Migration assay. Migration assays were performed in transwell 
inserts with 8-µm pore uncoated membrane filters (Corning 
Incorporated, Corning, NY, USA). Cells were trypsinized and 
seeded onto the upper chambers, in 0.2% FBS medium (4x104 
cells/well in 100 µl). The bottom chambers were filled with 
10% FBS medium (600 µl). Cells were allowed to migrate for 
6 h at 37˚C. Then, the upper side of the filters was carefully 
washed with cold PBS and non-migrated cells at the top of the 
filter were removed using a cotton swab. Cells that had migrated 
to the bottom of the filters were fixed and stained with Hema 3® 
Protocol Stain (Fisher Diagnostics, Middletown, CT, USA), and 
imaged with a Nikon Eclipse TE2000-U inverted epifluorescence 
microscope. Stained cells were counted in 10 pictures taken at 
x400 magnification. The average of cell number counted per field 
was multiplied by the ratio between the surfaces (total/counted) 
to determine the total number of migrated cells. Inhibition of 
migration was calculated normalizing data to control cells.
In vivo imaging and motility analysis. Cells were plated at a 
density of 2.5x104 cells in 35-mm Glass Bottom Dishes (MatTek 
Corporation, Ashland, OR, USA) and let to adhere overnight. 
Drug treatments were performed as described above. Images 
were recorded with a NikonTi Eclipse microscope equipped 
with a CO2 temperature controller atmosphere (Okolab, 
Ottaviano, NA, Italy) and a DS-QiMc-U2 12 bit camera. A 
10X Plan-Apochromatic Ph1 DL 0.25NA objective was used, 
yielding 0.91 µm/pixel in the acquired images. Total duration 
of recording is 15 h with a time frame interval of 5 min. Three 
plates were acquired for each of the control (CTRL) and treated 
(XII) MSC cultures for a total of six sequences of 180 frames 
each. Among these, three representative Regions of Interest 
(ROI) (labeled a,b,c) for each plate were considered for the 
motility analysis. In order to assess cells motility in treated and 
control MSC, we employed our tracking algorithm designed for 
this purpose. Image processing methods were devised to first 
detect the cell regions around the nuclei on each frame of the 
considered sequences through non-linear and morphological 
filters. Then, a combined feature-based and morphology-based 
tracking method was employed to track each cell center of mass 
(CM) along the sequence of frames to achieve the cell trajectory. 
Since the image illumination may change during the time-lapse 
sequence, phase contrast images could present artifacts that 
mislead the tracking stage. Also, during the acquisition of the six 
sequences, the repositioning error of the motorized stage where 
the plates were placed yielded x/y displacement on the imaging 
plane, this causing images not to be perfectly aligned. While the 
latter problem was easily fixed by phase-correlation registration 
methods, the former needed manual intervention. Trajectories 
recovered from the sequence of images were therefore analyzed 
by two experts to select only those with a high confidence, while 
the others were discarded.
Statistical analysis. All the images shown in this paper are 
representative of at least three independent experiments 
carried out under the same conditions. Statistical analysis 
were performed by ANOVA test followed by Bonferroni's 
multiple comparison test. P<0.05 were considered statistically 
significant. Data are expressed as the mean ± standard devia-
tion (SD).
Results
PI3K/AKT signaling pathway inhibition triggers actin remod-
eling of MSC. MSC were exposed for 30 or 60 min to increasing 
concentrations of well characterized PI3K/AKT inhibitors 
(25), in order to identify concentrations that do not compro-
mise cell viability (data not shown), and the morphology was 
observed by confocal microscopy (Fig. 1). In control MSC, 
PhalloidinFITC staining showed a dense network of F-actin 
bundles with tight, parallel stress fibers and adhesion foci and a 
well shaped migration front leading edge (Fig. 1A). Conversely, 
MSC treated with the PI3K Inhibitor LY 294002 were charac-
terized by reduced actin bundling and partial loss of cell-cell 
contacts and cell migration front (Fig. 1B). Moreover, the 
broad PI3K/Akt Inhibitor IV leds to collapse of actin bundles 
and complete loss of intercellular and focal adhesions, as 
visualized by vinculin staining (Fig. 1C). The AKT-dependent 
actin skeleton remodeling was monitored further in response 
to PH domain-dependent, non-ATP-competitive and isoform-
specific Inhibitors VIII and XII (AKTi VIII and XII), that 
potently inhibit Akt1/2 and Akt2 respectively, but not other 
AGC kinases (26), showing that both AKTi VIII and XII trig-
gered partial loss of actin fibers and cell rounding, whereas 
focal adhesions became restricted to discrete protruding 
portions of the cell periphery (Fig. 1D and E). Thus, in good 
agreement with previous reports in other cell types, alteration 
of cell morphology and actin skeleton organization by phar-
macological inhibition of PI3K/AKT indicates a key role of 
this pathway in the cytoskeletal remodeling of MSC.
As a read-out of treatment efficacy, phosphorylation of Akt 
S473 was monitored by western blot analysis. As expected, 
60 min upon treatment AKT S473 phosphorylation was 
decreased in a dose-dependent manner by both inhibitors 
(Fig. 2).
MSC migration and motility are affected by AKT inhibition. 
Defective migration is a major limitation in cell-based therapy. 
Therefore, in light of its well described role in actin remodeling 
linked to cell migration in several cell models, and based on the 
above observations, we aimed to investigate deeper AKT func-
tions in MSC. Since wound repair is a homeostatic process in 
which cell migration features prominently, we first examined the 
effect of AKT inhibition on the migration of MSC by means of 
the monolayer scratch wound healing assay.
Remarkably, while vehicle-treated MSC were able to close 
the scratch in 24 h, treatment with the AKTi XII, that selectively 
inhibits isoform 2, markedly blunted migration and after 24 h 
the wound closure was still incomplete (Fig. 3). In contrast, 
treatment with AKTi VIII, that inactivates both isoform 1 and 2, 
reduced migration to a lesser extent, resulting in an almost 
complete wound closure after 24 h.
Cell migration is not influenced by cell proliferation and cyto-
toxicity. Cell proliferation itself can promote wound closure. 
Besides, AKT inhibitors in turn might affect wound closure 
by slowing proliferation. To exclude this bias, proliferation of 
vehicle- or AKTi-treated MSC was calculated by Alamar Blue 
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Figure 1. Cytoskeletal remodeling of MSC exposed to PI3K/AKT Inhibitors. (A) Control MSC. (B) MSC treated for 30 min with 10 µM Inhibitor LY294002. 
(C) MSC treated for 30 min with 2.5 µM AKT Inhibitor IV. (D) MSC treated for 60 min 1 µM with AKT1/2 Inhibitor VIII. (E) MSC treated for 60 min with 
5 µM AKT2 Inhibitor XII. Immunofluorescence was performed using anti-vinculin antibody and FITC conjugated phalloidin actin, shown in red and green in 
Overlap panels, respectively. Hoechst staining is shown in blue in Overlap images. Pictures were taken using a 60X PlanApo VC Oil DIC N2 objective. White 
bracket in (A) pinpoints the migration front leading edge. Asterisks in B, C and D indicate the points of intercellular contacts loss. Scale bar is 50 µm in all panels. 
Representative pictures are shown.
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assay (Fig. 4). The test is based on the ability of metabolically 
active cells to convert the reagent from a blue to red colorimetric 
indicator. Damaged and non-viable cells have lower innate meta-
bolic activity and thus generate a proportionally lower signal. 
Total metabolic activity, checked at time zero (0 h) and after 
24 h, indicates no substantial variation following AKT inhibi-
tion. Thus, the drugs did not alter cell growth for the duration 
of the scratch wound test. Furthermore, cell cycle progression 
measured by flow cytometry confirmed cell viability and 
showed that cell cycle distribution was comparable between 
samples (Table I). Moreover, no remarkable apoptosis was 
detected, excluding cytotoxic effects of the above-mentioned 
drugs in this context. We conclude that the effects observed on 
MSC motility were independent of changes in MSC prolifera-
tion as well as alteration of metabolic activity.
MSC migration is compromised by AKT2 isoform inhibition. 
The effect of AKT inhibitors on MSC chemotactic mobility 
was assessed using 3D transwell migration assays. Consistent 
with previous reports (27), MSC control cells migrate toward 
the bottom chamber. Remarkably, treatment with the AKTi XII 
compound inhibited MSC migration, indicative of a promigra-
tory function of AKT2 in human MSC (Fig. 5). Conversely, 
Figure 2. AKT activity is efficiently blocked by specific inhibitors. Immuno-
blotting analysis of activated AKT (pAKT) and total AKT (AKT1/2) levels in 
vehicle and AKTi VIII (1, 2.5 µM) and XII (1, 2.5, 5 µM) 60 min treated MSC. 
Anti-actin shows equal loading.
Figure 3. AKT inhibitors affect MSC migration. (A) Phase contrast images of MSC treated with AKTi VIII and XII. (B) Graphical view showing the percentage 
of wound closure during 24 h. *p<0.05. AKTi XII delays wound closure.
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combined inhibition of AKT1 and AKT2 by Inhibitor VIII 
leads to a much weaker effect with respect to inactivation of 
AKT2 alone. Based on these results, we next tested AKTi XII 
on 2D-MSC motility through time-lapse in vivo microscopy. 
Fig. 6A shows the plot of measured mean velocity (µm/min) 
along the cell trajectories for the 18 analyzed sequences. Control 
cells show a higher velocity than treated cells. The measured 
mean velocity among the whole sequences is 9.22±0.98 µm/min 
for the control and 6.99±1.04 µm/min for treated cells. Cells 
treated with AKTi XII exhibit a 24% reduction of mean velocity.
We calculated also the Mean Square Displacement (MSD) 
<r2(∆t)> as a function of time lag ∆t (28). In Fig. 6B the loga-
rithmic plot of MSD is shown. Here, both control and treated 
cells exhibit super-diffusive motion for small ∆t (see for 
comparison the logarithmic slope of 2, which represents a quasi 
ballistic motion, and slope of 1, which corresponds to random 
walks in Brownian motion) and conversely, approach sub-diffu-
sive motion for large time lags. Besides, for each time interval 
considered, untreated cells migrated further than cells treated 
with AKTi XII. Overall, the movement and directionality anal-
yses show speed rate decrease and compromised status of the 
treated cell culture. An example of trajectories recovered from 
the sequence CTRL 3c and XII 3c is shown in Fig. 6C and D, 
respectively. These trajectories depict in an explicatory manner 
the role of inhibitor XII in cell motility. Control cell  trajectories 
showed higher displacements than those revealed on the treated 
MSC. Fig. 6E shows three subsequent frames (acquired at time 
lapse ∆t = 5 min) extracted from the same sequence showing 
tracked and labeled cells. While the movement of some cells 
is reduced (cell labels appear almost in the same position over 
this limited period of time), cells labeled 46 and 47 show a more 
dynamic interaction in this time frame. In general, considering 
the whole sequence, untreated cells tend to move faster than 
those treated with inhibitor XII.
Discussion
MSC are released from the bone marrow and enter into the 
peripheral circulation where, in homeostatic conditions, they 
contribute to tissue repair. Moreover, inflammatory chemokines, 
cytokines and growth factors released upon damage provide 
migratory cues that drive their mobilization to tissue injury sites 
to participate in immune modulation, tissue remodeling and 
wound healing (29). Taking advantage of their homing capaci-
ties, MSC targeted migration has been used as delivery vehicle 
for treatments against cancer, graft versus host disease, arthritis, 
multiple sclerosis, and many other diseases. MSC migration 
toward the inflammatory signals produced by the wounded 
environment has been widely studied, nevertheless the true 
migratory mechanism has yet to be elucidated.
PI3K/AKT signaling regulates multiple biological processes 
such as cell division, apoptosis, cell growth and cell migration. 
A series of recent studies documents the isoform-specific func-
tions of AKT family members 1 and 2 in regulation of cellular 
motility and migration by influencing numerous cellular targets 
involved in organization of the actin cytoskeleton, cellular 
interaction with the extracellular matrix, expression of motility 
genes and establishment of cellular polarity (30). In particular, 
AKT1 and AKT2 opposing functions on migration of breast 
cancer epithelial cell lines have been firmly established. AKT2 
promotes mammary epithelial cell migration and invasion, 
as shown by siRNA-mediated depletion of AKT2, through 
upregulation of β1-integrin and increased stability of palladin 
expression (6,31). Conversely, AKT1 negatively affects cell 
Table I. FACS analysis of cell cycle and apoptosis.a
 CTRL (%) VIII (%) XII (%)
G0/G1 phase
  0 h 90 94 94
  24 h 93 90 87
S phase
  0 h 0.7 0.8 0.7
  24 h 0.1 0.9 0.7
G2/M phase
  0 h 1.3 2.3 2.5
  24 h 3.6 1.4 2.1
h-apoptosis
  0 h 6.5 2.1 1.6
  24 h 1.4 6.6 7.3
aFor detection and quantification of cell cycle distribution, samples 
containing 5x105 cells were harvested by centrifugation, fixed in cold 
ethanol and subjected to propidium iodide (PI) staining.
Figure 4. Cytotoxicity and proliferation of MSC upon AKT inhibition. % of 
Alamar Blue reduction at time zero (0 h) and 24 h after drug-treatment.
Figure 5. Effect of AKT Inhibitors on MSC migration. MSC migration was 
examined after AKTi VIII and XII treatment by transwell migration assay. 
*p<0.05. Error bars indicate SD.
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migration by either transcriptional regulation of motility genes, 
or actin organization and formation of stress fibers and cellular 
interaction with the extracellular matrix (6,31). The role of AKT 
isoforms in other cell models is less clear. In particular, both 
AKT1 and 2 seem to play an inhibitory role in prostate cancer 
cell migration and invasion (32).
In this study, we examined human MSC migration and 
wound closure potential in vitro. We also used selective inhibi-
tors of AKT isoforms 1 and 2 to dissect the contribution of 
each isoform to migration, by selectively blocking either 
isoform 2 only or both isoforms. Our results showed that both 
isoforms are expressed at high level in MSC obtained from 
Figure 6. In vivo cell tracking analysis. (A) Mean velocity (Y-axis) of cell tracks in 9 different image sequences (X-axis ) of control (CTRL) and treated (XII) MSC. 
Error bar indicates SD. (B) MSD <r2(∆t)> versus time lag ∆t for CTRL and XII MSC. Thin lines indicate logarithmic slopes of 1 and 2. (C and D) Trajectory plot 
of tracked cells in the sequence (C) CTRL 3c and (D) XII 3c. XY-plane units are in pixel, whilst Z unit is video frame number. (E) Three subsequent frames (∆t = 
5 min) extracted from the sequence CTRL 3c showing tracked cells.
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three different individual and cultured in vitro. Reactivity 
to anti-pSer473 further demonstrates their activity. Of note, 
only selective inhibition of AKT2 effectively counteracted 
wound closure, whereas dual inhibition of AKT1 and 2 was 
less effective. An explanation for this result comes from 
previous reports, showing that AKT1 inhibition can lead to 
increased cell migration. Hence, in our cell system blocking 
both isoforms weakens the efficacy of AKT2 inhibition. To 
our knowledge, this is the first study that provides evidence 
for an isoform-specific positive role of AKT in regulating 
migration of human mesenchymal stem cells.
Although we have a deep understanding of the mechanisms 
by which the AKT kinase is regulated, what ultimately quali-
fies a kinase are its substrates, as it is very well known that 
the phosphorylation of specific substrates determines most of 
protein kinase cellular functions (33). Recently, the mechano-
sensor and actin bundling protein Ankrd2 was demonstrated 
to be a specific AKT2 substrate (14). It is therefore tempting to 
speculate that AKT2 might promote MSC migration through 
direct phosphorylation of Ankrd2. However, the relative contri-
bution, if any, of Ankrd2 to the phenotypic changes associated 
with activation of AKT2 needs deeper investigation.
MSC are used with increasing frequency in laboratories 
and clinics as potential treatments for injury and tissue regen-
eration. The fundamental mechanisms through which MSC 
migrate to sites of injury remains undefined. Our finding that 
AKT2 is required for directed chemotaxis by MSC offers 
a potential target of clinical relevance for enhancing or 
blocking the effects of migrating MSC.
Acknowledgements
The authors are grateful to Dr Panagiota Dimopoulou 
for editorial assistance. Research was supported in part 
by Progetto MIUR-FIRB (accordi di programma 2010 
RBAP1044), MIUR-FIRB (Human Proteome Net), by 
Italian MIUR-Programma di Ricerca di Rilevante Interesse 
Nazionale Prin 2008 and by Italian Ministry of Health (project 
IOR-2006-422755). SM acknowledges the ‘International 
short term mobility program’ from Italian CNR.
References
  1. Charbord P: Bone marrow mesenchymal stem cells: historical 
overview and concepts. Hum Gene Ther 21: 1045-1056, 2010.
  2. Devine SM, Cobbs C, Jennings M, Bartholomew A and 
Hoffman R: Mesenchymal stem cells distribute to a wide range 
of tissues following systemic infusion into nonhuman primates. 
Blood 101: 2999-3001, 2010.
  3. Chamberlain G, Fox J, Ashton B and Middleton J: Concise 
review: mesenchymal stem cells: their phenotype, differentiation 
capacity, immunological features, and potential for homing. Stem 
Cells 25: 2739-2749, 2007.
  4. Kang SK, Shin IS, Ko MS, Jo JY and Ra JC: Journey of mesen-
chymal stem cells for homing: strategies to enhance efficacy and 
safety of stem cell therapy. Stem Cells Int 2012: 342968, 2012.
  5. Manning BD and Cantley LC: AKT/PKB signaling: navigating 
downstream. Cell 129: 1261-1274, 2007.
  6. Chin YR and Toker A: Akt isoform-specific signaling in breast 
cancer: uncovering an anti-migratory role for palladin. Cell Adh 
Migr 5: 211-214, 2011.
  7. Worster DT, Schmelzle T, Solimini NL, Lightcap ES, Millard B, 
Mills GB, Brugge JS and Albeck JG: Akt and ERK control the 
proliferative response of mammary epithelial cells to the growth 
factors IGF-1 and EGF through the cell cycle inhibitor p57Kip2. 
Sci Signal 5: ra19, 2012.
  8. Kakinuma N, Roy BC, Zhu Y, Wang Y and Kiyama R: Kank 
regulates RhoA-dependent formation of actin stress fibers and 
cell migration via 14-3-3 in PI3K-Akt signaling. J Cell Biol 181: 
537-549, 2008.
  9. Cenni V, Sirri A, Riccio M, Lattanzi G, Santi S, de Pol A, 
Maraldi NM and Marmiroli S: Targeting of the Akt/PKB kinase 
to the actin skeleton. Cell Mol Life Sci 60: 2710-2720, 2003.
10. Scita G, Tenca P, Frittoli E, Tocchetti A, Innocenti M, Giardina G 
and Di Fiore PP: Signaling from Ras to Rac and beyond: not just 
a matter of GEFs. EMBO J 19: 2393-2398, 2000.
11. Qian Y, Corum L, Meng Q, Blenis J, Zheng JZ, Shi X, Flynn DC 
and Jiang BH: PI3K induced actin filament remodeling through 
Akt and p70S6K1: implication of essential role in cell migration. 
Am J Physiol Cell Physiol 286: C153-C163, 2004.
12. Enomoto A, Murakami H, Asai N, Morone N, Watanabe T, 
Kawai K, Murakumo Y, Usukura J, Kaibuchi K and Takahashi M: 
Akt/PKB regulates actin organization and cell motility via 
Girdin/APE. Dev Cell 9: 389-402, 2005.
13. Yoeli-Lerner M, Yiu GK, Rabinovitz I, Erhardt P, Jauliac S and 
Toker A: Akt blocks breast cancer cell motility and invasion 
through the transcription factor NFAT. Mol Cell 20: 539-550, 
2005.
14. Cenni V, Bavelloni A, Beretti F, Tagliavini F, Manzoli L, Lattanzi G, 
Maraldi NM, Cocco L and Marmiroli S: Ankrd2/ARPP is a novel 
Akt2 specific substrate and regulates myogenic differentiation 
upon cellular exposure to H(2)O(2). Mol Biol Cell 22: 2946-2956, 
2011.
15. Irie HY, Pearline RV, Grueneberg D, Hsia M, Ravichandran P, 
Kothari N, Natesan S and Brugge JS: Distinct roles of Akt1 and 
Akt2 in regulating cell migration and epithelial-mesenchymal 
transition. J Cell Biol 171: 1023-1034, 2005.
16. Pierini M, Dozza B, Lucarelli E, Tazzari PL, Ricci F, Remondini D, 
di Bella C, Giannini S and Donati D: Efficient isolation and enrich-
ment of mesenchymal stem cells from bone marrow. Cytotherapy 
14: 686-693, 2012.
17. Maraldi T, Riccio M, Resca E, Pisciotta A, La Sala GB, 
Ferrari A, Bruzzesi G, Motta A, Migliaresi C, Marzona L and 
De Pol A: Human amniotic fluid stem cells seeded in fibroin 
scaffold produce in vivo mineralized matrix. Tissue Eng Part A 
17: 2833-2843, 2011.
18. Dozza B, Gobbi G, Lucarelli E, Pierini M, Bella CD, Frisoni T, 
Tazzari PL, Ricci F, Mirandola P, Carubbi C, Giannini S, Donati D 
and Vitale M: A rapid method for obtaining mesenchymal stem 
cells and platelets from bone marrow aspirate. J Tissue Eng Regen 
Med: June 19, 2012 (Epub ahead of print). doi: 10.1002/term.1551.
19. Maraldi T, Riccio M, Sena P, Marzona L, Nicoli A, La Marca A, 
Marmiroli S, Bertacchini J, La Sala G and De Pol A: MATER 
protein as substrate of PKCepsilon in human cumulus cells. Mol 
Hum Reprod 15: 499-506, 2009.
20. Cenni V, Sabatelli P, Mattioli E, Marmiroli S, Capanni C, 
Ognibene A, Squarzoni S, Maraldi NM, Bonne G, Columbaro M, 
Merlini L and Lattanzi G: Lamin A N-terminal phosphorylation is 
associated with myoblast activation: impairment in Emery-Dreifuss 
muscular dystrophy. J Med Genet 42: 214-220, 2005.
21. Duca M, Dozza B, Lucarelli E, Santi S, Di Giorgio A and 
Barbarella G: Fluorescent labeling of human mesenchymal stem 
cells by thiophene fluorophores conjugated to a lipophilic carrier. 
Chem Commun (Camb) 46: 7948-7950, 2010.
22. Maraldi T, Bertacchini J, Benincasa M, Guida M, De Pol A, 
Liotta LA, Petricoin E, Cocco L and Marmiroli S: Reverse-phase 
protein microarrays (RPPA) as a diagnostic and therapeutic guide 
in multidrug resistant leukemia. Int J Oncol 38: 427-435, 2011.
23. Gebäck T, Schulz MM, Koumoutsakos P and Detmar M: 
TScratch: a novel and simple software tool for automated analysis 
of monolayer wound healing assays. Biotechniques 46: 265-274, 
2009.
24. Mirandola P, Sponzilli I, Gobbi G, Marmiroli S, Rinaldi L, 
Binazzi R, Piccari GG, Ramazzotti G, Gaboardi GC, Cocco L 
and Vitale M: Anticancer agents sensitize osteosarcoma cells to 
TNF-related apoptosis-inducing ligand downmodulating IAP 
family proteins. Int J Oncol 28: 127-133, 2006.
25. Martelli AM, Evangelisti C, Follo MY, Ramazzotti G, Fini  M, 
Giardino R, Manzoli L, McCubrey JA and Cocco L: Targeting 
the phosphatidylinositol 3-kinase/Akt/mammalian target of 
rapamycin signaling network in cancer stem cells. Curr Med 
Chem 18: 2715-2726, 2011.
26. Wu W-I, Voegtli WC, Sturgis HL, Dizon FP, Vigers GPA and 
Brandhuber BJ: Crystal structure of human AKT1 with an allo-
steric inhibitor reveals a new mode of kinase inhibition. PLoS 
One 5: e12913, 2010.
INTERNATIONAL JOURNAL OF ONCOLOGY  9
27. Chin YR and Toker A: The actin-bundling protein palladin is an 
Akt1-specific substrate that regulates breast cancer cell migration. 
Mol Cell 38: 333-344, 2010.
28. Nocentini S, Reginensi D, Garcia S, Carulla P, Moreno-Flores MT, 
Wandosell F, Trepat X, Bribian A and Del Río JA: Myelin-
associated proteins block the migration of olfactory ensheathing 
cells: an in vitro study using single-cell tracking and traction force 
microscopy. Cell Mol Life Sci 2012.
29. Fox JM, Chamberlain G, Ashton BA and Middleton J: Recent 
advances into the understanding of mesenchymal stem cell traf-
ficking. Br J Haematol 137: 491-502, 2007.
30. Stambolic V and Woodgett JR: Functional distinctions of 
protein kinase B/AKT isoforms defined by their influence on cell 
migration. Trends Cell Biol 16: 461-466, 2006.
31. Toker A: Achieving specificity in Akt signaling in cancer. Adv 
Enzyme Regul 52: 78-87, 2012.
32. Virtakoivu R, Pellinen T, Rantala JK, Perälä M and Ivaska J: 
Distinct roles of AKT isoforms in regulating β1-integrin activity, 
migration, and invasion in prostate cancer. Mol Biol Cell 23: 
3357-3369, 2012.
33. Moritz A, Li Y, Guo A, Villén J, Wang Y, MacNeill J, Kornhauser J, 
Sprott K, Zhou J, Possemato A, Ren JM, Hornbeck P, Cantley LC, 
Gygi SP, Rush J and Comb MJ: AKT-RSK-S6 kinase signaling 
networks activated by oncogenic receptor tyrosine kinases. Sci 
Signal 3: ra64, 2010.
